Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-1904 ENCO-BRAF
2024-515944-22-00Phase 2Authorised
- Sponsor
- IFCT
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of encorafenib and binimetinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by IFCT. Primary endpoint: Objective Response Rate (ORR) by investigator. Planned start Oct 2024; status: authorised.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515944-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515944-22-00.